Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

FDA Section 361 Compliance Checklist for HCT/Ps

Published November 21, 2026

Statutory Criteria (21 CFR 1271.10(a))
4 Core Requirements

An HCT/P must satisfy minimal manipulation, homologous use, no prohibited article combinations, and specific metabolic/systemic limitations to remain under Section 361.

Primary Regulatory Pathways
Section 361 vs. Section 351

Human tissues are regulated either solely under Section 361 of the PHS Act (cGTP rules) or under Section 351 as biological drugs/devices requiring premarket approval.

Chain-of-Custody Traceability
Donor-to-Recipient Tracking

21 CFR Part 1271 requires unique identification coding and summary donor eligibility records to accompany tissues to prevent communicable disease transmission.

A clinical FDA Section 361 compliance checklist for human cellular tissue products operationalizes procurement oversight by confirming an HCT/P distributor holds an active FDA Form 3356 registration, maintains certified Current Good Tissue Practice (cGTP) handling, and validates full donor eligibility documentation. Because treating practices face direct regulatory liability when administering products that fail 361 exemption criteria and trigger unapproved Section 351 biologic classifications, robust vendor screening is an essential risk-mitigation protocol. Use the actionable audit steps below to evaluate supplier quality agreements, inspect chain-of-custody records, and secure your practice's biologics formulary.

Understanding the Regulatory Framework: Section 361 vs. Section 351

When medical practices evaluate regenerative biologics—such as amniotic allografts, Wharton's Jelly, cord blood, or extracellular vesicles—the primary operational risk lies in regulatory misclassification. Under the Public Health Service (PHS) Act, the FDA categorizes human cellular and tissue-based products into two distinct pathways: Section 361 and Section 351.

Products regulated solely under Section 361 and 21 CFR Part 1271 are not required to undergo premarket approval (such as a Biologics License Application or Investigational New Drug application), provided they strictly satisfy four regulatory criteria. If a product fails to meet even one of these criteria, it is regulated as a drug, device, or biological product under Section 351, requiring formal FDA premarket clearance before commercial distribution.

For a practice manager, relying on a sales representative's verbal assurance that a product is "FDA registered" is insufficient. Tissue establishment registration is an administrative requirement under 21 CFR Part 1271, not an FDA approval or a confirmation that a specific product qualifies for the Section 361 pathway. Due diligence happens at the practice level through structured vendor auditing.

The FDA Section 361 Compliance Checklist for Human Cellular Tissue Products

Practice administrators and compliance officers should integrate this checklist into their standard vendor onboarding and annual review protocols before purchasing any HCT/P.

1. Verify the Four Statutory Criteria (21 CFR 1271.10(a))

  • Minimal Manipulation: Confirm how the tissue is processed. For structural tissue (such as amniotic membrane or Wharton's Jelly connective tissue), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics.
  • Homologous Use: Review the vendor's labeling, package inserts, and marketing materials. The product must be promoted solely to perform the same basic function or functions in the recipient as in the donor (e.g., serving as a protective covering or structural cushion).
  • No Prohibited Combinations: Verify that the HCT/P is not combined with another article, except for water, crystalloids, or a sterilizing, preserving, or storing agent, provided that the addition does not raise new clinical safety concerns.
  • Systemic Effect / Metabolic Dependence: Ensure that the product either does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or, if it does, that it is intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

2. Audit Supplier Registration and Inspection History

  • FDA Establishment Registration (FEI Number): Obtain the processing lab's FDA Establishment Identifier and verify its active status directly in the FDA Human Cell and Tissue Establishment Registration (HCTER) public database.
  • Establishment Functions & Tissue Types: Confirm in the HCTER database that the laboratory is registered for the specific functions (e.g., recovery, screening, processing, packaging, distribution) and the exact tissue types they are selling to your practice.
  • Inspection and Enforcement History: Search the FDA Data Dashboard and Warning Letters database for the manufacturer and any parent entities. Check for Form FDA 483 observations, untitled letters, or warning letters regarding unapproved new drugs or Current Good Tissue Practice (cGTP) deviations.
  • Accreditation Verification: Request current certificates of accreditation from recognized bodies, such as the American Association of Tissue Banks (AATB), if applicable to the tissue type.

3. Validate Donor Eligibility and Testing Documentation

  • Summary of Records: Under 21 CFR 1271.290, every HCT/P must be accompanied by a summary of records confirming that a donor-eligibility determination was made and that the donor was found eligible based on screening and testing.
  • Communicable Disease Testing: Ensure the accompanying documentation verifies negative or non-reactive results for required infectious disease panels (including HIV-1/2, HBV, HCV, Treponema pallidum, HTLV-I/II where applicable, and CMV for leukocyte-rich tissues) performed by an FDA-registered, CLIA-certified laboratory using FDA-licensed, approved, or cleared donor screening tests.
  • Distinct Identification Code: Verify that each tissue unit features a unique alphanumeric tracking code linking the allograft to the donor record while maintaining donor anonymity.

4. Assess Marketing Claims and Promotional Alignment

  • Labeling Review: Audit the supplier's brochures, website, and clinical educational sheets. Vendors making therapeutic claims to treat, cure, or mitigate specific diseases (e.g., osteoarthritis, neuropathy, systemic autoimmune conditions) without an approved BLA or IND are triggering Section 351 classification through intended use.
  • Practice Marketing Alignment: Ensure your clinic's internal patient intake forms, website copy, and social media channels do not make disease-specific efficacy claims for 361 products, as clinic-level promotional statements can also alter how regulators view intended use.

5. Confirm Cold-Chain Logistics and Adverse Event SOPs

  • Storage and Receiving Logs: Establish standard operating procedures (SOPs) for receiving cryogenically frozen, refrigerated, or ambient-temperature tissues. Document container integrity and temperature validation upon arrival.
  • Recipient Tracking Logs: Maintain a master tissue log that records the product lot number, unique donor identification code, expiration date, date of administration, and recipient patient identifier to facilitate rapid look-backs or recalls.
  • Adverse Reaction Reporting: Confirm the vendor has a formal protocol for investigating and reporting suspected communicable disease transmission or adverse reactions under 21 CFR 1271.350.

Clinical Considerations for Physicians and Medical Directors

While practice administrators manage vendor qualification and documentation, treating clinicians bear the responsibility for how regenerative modalities are integrated into patient care. Physicians in orthopedics, sports medicine, and pain management frequently evaluate allografts alongside autologous therapies (such as platelet-rich plasma) and non-invasive energy modalities.

From a clinical governance perspective, physicians should consider the following:

  • Distinguishing Structural vs. Cellular Mechanisms: Understanding the physical properties of the tissue—such as the extracellular matrix scaffolding of amniotic tissue vs. autologous blood-derived concentrates—helps clinicians align product selection with compliant homologous use parameters.
  • Informed Consent Specificity: Standard procedural consent forms are rarely sufficient for HCT/Ps. Clinical directors should implement specialized informed consent documents that clearly explain the human tissue origin of the allograft, the screening process and residual theoretical risks of communicable disease transmission, the regulatory status of the product, and cash-pay financial responsibility.
  • Multimodal Protocol Design: Many practices reduce their reliance on high-risk or ambiguously classified biologics by pairing compliant autologous PRP preparations with cleared regenerative devices like extracorporeal shockwave therapy (ECSWT) or high-power laser therapy (HPLT). Combining mechanical or photobiomodulation modalities with compliant biologics gives clinicians versatile, defensible care pathways.

Evaluating Distributors vs. Direct Manufacturers

Practices often source biologics through a specialized distributor rather than managing separate accounts with multiple tissue banks. When working with a distributor, the compliance checklist applies to both the original processing laboratory and the distribution partner.

A qualified medical distributor should hold appropriate state licensure (such as a Texas medical device distributor license), maintain transparent relationships with their partner laboratories, and provide unredacted regulatory packets upon request. At Dallas Regenerative Solutions, we support practices across multiple specialties by vetting supply partners for quality documentation and helping administrators organize their procurement workflows.

What This Means for Your Practice

Building a compliant regenerative service line requires proactive operational governance rather than reactive troubleshooting. Practice managers should take the following concrete next steps:

  1. Build a Physical and Digital Compliance Binder: Create a dedicated file for every HCT/P in your inventory containing the lab's current FDA HCTER printout, CLIA certificates for testing labs, sample package inserts, and tissue tracking SOPs.
  2. Audit Existing Inventory and Marketing: Review your current biologics suppliers against the four criteria of 21 CFR 1271.10(a) and scrub your practice website of any unauthorized disease claims associated with allografts.
  3. Standardize Receiving and Tracking Workflows: Train clinical staff to log every tissue serial number upon receipt and link each unit directly to the patient's electronic health record (EHR) at the time of administration.

If your practice is auditing its current biologics supply chain or evaluating compliant regenerative technologies to expand your clinical offerings, contact our team to schedule an operational consultation.

Frequently asked questions

Does FDA establishment registration mean an HCT/P is FDA-approved?
No. Tissue establishment registration under 21 CFR Part 1271 is an administrative requirement where facilities list their operations and tissue types with the FDA. It does not constitute FDA approval, clearance, or an official determination that a specific product meets all Section 361 criteria.
What is the difference between a Section 361 and a Section 351 biologic?
Section 361 products meet all four criteria in 21 CFR 1271.10(a)—including minimal manipulation and homologous use—and are regulated solely to prevent communicable disease transmission without premarket approval. Section 351 products fail one or more of these criteria and are regulated as drugs, devices, or biological products requiring an IND or BLA.
How does a vendor's marketing affect a product's Section 361 status?
Homologous use is determined in part by the labeling, advertising, and other indications of the manufacturer's objective intent. If a supplier promotes a tissue product to treat specific systemic or non-homologous medical conditions, the FDA may classify the product under Section 351 regardless of how minimally it was processed.
What documentation must accompany every HCT/P shipment to a clinic?
Under 21 CFR 1271.290, every HCT/P must be accompanied by a distinct identification code, package insert instructions, and a summary of records confirming that a donor-eligibility determination was completed and that the donor tested negative for relevant communicable disease agents.
How should a medical practice track HCT/Ps internally?
Practices should maintain a master tissue tracking log that records the receipt date, storage temperature verification, unique donor identification code, expiration date, date of clinical use, and the recipient patient's medical record number. This ensures full chain-of-custody traceability from the processing laboratory to the patient.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →